Search | Clinical Trials Finder

Conditions: Dry Eye
Interventions: VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle; Drug
Lead sponsor: VivaVision Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Choroidal Neovascularization, Age-related Macular Degeneration
Interventions: hI-con1, ranibizumab, Sham injection; Biological · Other
Lead sponsor: Iconic Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 48
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more

Conditions: Thyroid Eye Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more

Conditions: Age-Related Macular Degeneration
Interventions: Active Comparator CT1812, Placebo Comparator; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 91
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Rowland Heights, California • San Francisco, California • Miami, Florida + 10 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Dry Eye Syndrome
Interventions: TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Presbyopia Condition
Interventions: Test lens, Control lens; Device
Lead sponsor: Bruno Vision Care; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Longwood, Florida • Pittsburg, Kansas • Warwick, Rhode Island

Conditions: Tourette Syndrome
Interventions: d-cycloserine, Placebo pill, Behavior Therapy; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mydriasis
Interventions: MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop; Combination Product · Drug
Lead sponsor: Eyenovia Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Artesia, California

Conditions: Dry Eye Syndromes
Interventions: CP-690,550, Cyclosporine, CP-690,550 Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Overweight and Obesity
Interventions: Experimental: Web-based only (WO) weight intervention, Experimental: WO plus peer-led discussion board (WD), Experimental: WO & professional email counseling (WE); Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Sham; Drug · Other
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Geographic Atrophy
Interventions: Danicopan, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 49
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more

Conditions: Healthy Volunteer
Interventions: Urolithin A, Placebo; Dietary Supplement
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ocular Inflammation
Interventions: rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle; Drug
Lead sponsor: Evolutec Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Ocular Hypertension, Open-angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: Up to 99 Years
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Wet Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 59
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more

Conditions: Status Asthmaticus
Interventions: Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer; Device
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 12 Months to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Spinal Cord Injuries
Interventions: AIH, Walk, Strength; Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Search by objective public record fields.

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

A Randomized, Active-Controlled, Double-Masked, Crossover Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens for Presbyopia Extended Depth of Focus (EDOF)

D-cycloserine Augmented Treatment for Youth With Tic Disorders

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial

Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury